This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Mirvetuximab Soravtansine
- DrugBank Accession Number
- DB12489
- Background
Mirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- IMGN853
- Mirvetuximab Soravtansine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Mirvetuximab Soravtansine. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Mirvetuximab Soravtansine. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Mirvetuximab Soravtansine. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Mirvetuximab Soravtansine. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Mirvetuximab Soravtansine. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Mirvetuximab Soravtansine. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Mirvetuximab Soravtansine. Albendazole The metabolism of Albendazole can be decreased when combined with Mirvetuximab Soravtansine. Alectinib The metabolism of Alectinib can be decreased when combined with Mirvetuximab Soravtansine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mirvetuximab Soravtansine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Anti-Bacterial Agents
- Antibodies
- Antibodies, Monoclonal
- Blood Proteins
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Globulins
- Immunoglobulins
- Immunologic Factors
- Immunoproteins
- Lactams, Macrocyclic
- Lactones
- Macrolides
- Proteins
- Serum Globulins
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 98DE7VN88D
- CAS number
- 1453084-37-1
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]
Drug created at October 20, 2016 22:35 / Updated at February 21, 2021 18:53